An update on recent randomized clinical trials in systemic sclerosis.

Area of Science:

• Rheumatology
• Immunology
• Pulmonology

Background:

• Systemic sclerosis (SSc) is a heterogeneous autoimmune disease involving inflammation, vasculopathy, and fibrosis.
• Pathogenic pathways in SSc are increasingly understood, revealing potential therapeutic targets.
• Recent years have seen significant advancements in SSc research and treatment development.

Purpose of the Study:

• To provide an overview of recent clinical trials in Systemic Sclerosis (SSc) management.
• To highlight progress in identifying and testing therapeutic targets for SSc.
• To discuss evolving clinical trial designs and endpoints in SSc research.

Main Methods:

• Review of recent clinical trials in Systemic Sclerosis.
• Analysis of therapeutic strategies including targeted therapies and immunosuppressants.
• Examination of changes in clinical trial design, inclusion criteria, and endpoints.

Main Results:

• The SENSCIS trial led to the approval of Nintedanib for SSc-related interstitial lung disease.
• Most trials focused on immunosuppressive therapy with limited approved agents for SSc.
• Evolving trial designs now enrich for progressive patients and incorporate patient-reported outcomes.

Conclusions:

• Significant progress has been made in SSc therapeutics, particularly for interstitial lung disease.
• Further research is needed to identify effective immunosuppressants and combination therapies for SSc.
• Evolving clinical trial methodologies are crucial for advancing SSc treatment.